Attenuation of the early anterior negativity of median nerve somatosensory evoked potential in the MPTP-treated monkey.
Median nerve somatosensory evoked potentials (SEP) were recorded in 7 Cynomolgus monkeys, before and after the administration of N-Methyl 1,4 Phenyl 1,2,3,6 tetrahydropiridine (MPTP), a neurotoxin which induces a parkinsonian syndrome in primates. Following MPTP administration, the amplitude of the negative component recorded at 15 ms over the frontal derivations (N15) decreased by 70% or more. This amplitude reduction was not modified by administration of dopamine precursors. These findings shed light on recent findings in human parkinsonian patients.
Onofrj
M
M
Department of Neurology, State University of Chieti, Italy.
Ghilardi
M F
MF
Basciani
M
M
Martinez-Tica
J
J
Glover
A
A
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D004558:Electric Stimulation; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects*; D005625:Frontal Lobe / Q000502:physiology; D007275:Injections, Intravenous; D007649:Ketamine / Q000494:pharmacology; D008252:Macaca fascicularis; D008475:Median Nerve / Q000187:drug effects*; D010296:Parietal Lobe / Q000502:physiology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology
D007649:Ketamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine